PET/CT Scan with FNP-59 for High Cholesterol

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
High Cholesterol+2 MorePET/CT Scan with FNP-59 - CombinationProduct
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial will test if a low dose of a fluorine-18-based NP-59 can be used to image the adrenal gland in healthy people and people with adrenal conditions.

Eligible Conditions
  • High Cholesterol
  • High Blood Pressure
  • Radiotracer

Treatment Effectiveness

Study Objectives

1 Primary · 1 Secondary · Reporting Duration: Day 4

Day 0, Day 4
Change in [18F]FNP-59 chemistry uptake as measured by the standardized uptake value (SUV) based gland segmentation
Day 4
PET/CT scan

Trial Safety

Trial Design

3 Treatment Groups

Dexamethasone (Group 2)
1 of 3
Cosyntropin (Group 3)
1 of 3
Adrenal pathology (Group 4)
1 of 3

Experimental Treatment

24 Total Participants · 3 Treatment Groups

Primary Treatment: PET/CT Scan with FNP-59 · No Placebo Group · Phase < 1

Dexamethasone (Group 2)Experimental Group · 2 Interventions: PET/CT Scan with FNP-59, Dexamethasone (Group 2) · Intervention Types: CombinationProduct, Drug
Cosyntropin (Group 3)Experimental Group · 2 Interventions: PET/CT Scan with FNP-59, Cosyntropin (Group 3) · Intervention Types: CombinationProduct, Drug
Adrenal pathology (Group 4)
CombinationProduct
Experimental Group · 1 Intervention: PET/CT Scan with FNP-59 · Intervention Types: CombinationProduct

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: day 4

Who is running the clinical trial?

Benjamin VigliantiLead Sponsor
1 Previous Clinical Trials
6 Total Patients Enrolled
Benjamin L Viglianti, M.D, Ph.D.Principal InvestigatorUniversity of Michigan

Eligibility Criteria

Age 18+ · All Participants · 1 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you: